David · Meta IG Feed · Pharmacy-Transparent Plan · consideration
“How to tell a serious compounded program from a warning-letter operator.”
Full structured brief
{
"banned_phrases": [
"generic",
"affordable",
"cheap",
"guaranteed",
"cure",
"insurance",
"lose X pounds"
],
"channel": "meta-ig-feed",
"core_tension": "He\u0027s evaluating vendors. The good ones and the bad ones look identical on the surface.",
"evidence_hook": "FDA issued 30+ warning letters to compounding telehealth operators; named pharmacy + COA trail is a reliable signal.",
"funnel_stage": "consideration",
"key_message": "Pharmacy section vague? Close the tab. Named pharmacies with COA documentation? Worth a closer look.",
"offer": "pharmacy-transparency",
"persona": "david",
"reframe": "Three due-diligence questions separate compliant operators from the ones with enforcement risk.",
"tone_notes": "Analytical, peer-to-peer. Respect his ability to evaluate evidence."
}
3 variants
How to spot a compounded program that will still be operating in 2027.
Durable compounding operators share three characteristics: named 503A pharmacies, documented clinician evaluation for every patient, and third-party COA testing. Eudaven was built to that standard from day one — not retr…
Read our pharmacy partner page
Read the pharmacy section first. If it's vague, close the tab.
The warning-letter cluster in compounded GLP-1 telehealth shares a common thread: operators who couldn't name who filled the prescription. Eudaven's pharmacy partners — Belmar, Strive, Epiq, Casa — are named publicly, op…
Start a clinical intake
Patient-specific compounding requires patient-specific clinician evaluation. Both should be visible to you.
At Eudaven, every compounded GLP-1 prescription is preceded by a licensed clinician review of your labs, history, and clinical context. Your medication is filled by a named 503A partner pharmacy with COA documentation av…
Talk to a licensed clinician